Aptamer Group plc (LON:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, will announce its interim results for the six months ended 31 December 2024 on Tuesday, 11 March 2025.
Aptamer Group to publish interim results on Tuesday 11th March
- Written by: Amilia Stone
Latest Company News
Aptamer Group has entered into its first licensing agreement with Twist Bioscience, granting a non-exclusive licence for the use of an Optimer® binder in hot-start PCR and next-generation sequencing products.
Aptamer Group is holding its AGM today in York, where the Chairman will outline continued commercial progress, recent contract wins with major pharmaceutical companies, and an FY26 order book of £1.95 million.
Aptamer Group announced two new contracts worth £192,000, including a fourth engagement with a top five global pharmaceutical company and a new deal targeting acute myeloid leukaemia.
Aptamer Group delivered strong progress in FY2025, achieving a 40% revenue increase and expanding its portfolio of licensable Optimer® assets from four to eleven.
Aptamer Group has announced its full-year results for the twelve months ended 30 June 2025, delivering a 40% increase in revenue to £1.2 million and expanding its Optimer® licensing portfolio from four to eleven assets.
Aptamer Group has signed a new agreement with an existing partner to develop Optimer® binders targeting two proteins for biomarker research.
